Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular and cancer therapy. Nuvelo’s development pipeline includes three acute cardiovascular programs: alfimeprase, a direct-acting thrombolytic in Phase 3 clinical trials for the treatment of thrombotic-related disorders; rNAPc2, an anticoagulant that inhibits the factor VIIa and tissue factor protease complex that recently completed Phase 2 clinical development in acute coronary syndromes; and preclinical candidate NU172, a direct thrombin inhibitor for use as a short-acting anticoagulation during medical ( www.nuvelo.com )
Nuvelo , Inc.
675 Almanor Avenue
Sunnyvale, California 94085
USA
Tel: (408) 215-4000
Fax: (408) 215-4001